{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Graft+vs+Host+Disease", "query": { "condition": "Chronic Graft vs Host Disease" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 479, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Graft+vs+Host+Disease&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:49:33.464Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00350545", "title": "A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Graft vs Host Disease" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 37, "start_date": "2006-08", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350545" }, { "nct_id": "NCT01663766", "title": "Phase I Study of Milatuzumab for Graft Versus Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "GVHD (Acute or Chronic)", "Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)", "Myelodysplastic Syndrome", "Chronic Myelogenous Leukemia (CML)", "Multiple Myeloma (MM)", "Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)", "Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)" ], "interventions": [ { "name": "milatuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-12", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2021-08-19", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663766" }, { "nct_id": "NCT01911039", "title": "Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Versus Host Disease", "Allogeneic Hematopoietic Cell Transplant Recipient" ], "interventions": [ { "name": "Regulatory T Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Laura Johnston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-07", "completion_date": "2018-07-31", "has_results": false, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01911039" }, { "nct_id": "NCT01276639", "title": "A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo/CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 901, "start_date": "2011-03", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-09-19", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Irvine, California • San Diego, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276639" }, { "nct_id": "NCT04063215", "title": "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "HB-adMSCs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hope Biosciences LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2020-01-01", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04063215" }, { "nct_id": "NCT01789255", "title": "Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "B-cell Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Graft Versus Host Disease", "Intraocular Lymphoma", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ringed Sideroblasts", "Refractory Chronic Lymphocytic Leukemia", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Central Nervous System Hodgkin Lymphoma", "Secondary Central Nervous System Non-Hodgkin Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Small Lymphocytic Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2013-06", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01789255" }, { "nct_id": "NCT02986334", "title": "Placebo In Chronic Back Pain (Phase 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Low Back Pain" ], "interventions": [ { "name": "Naproxen", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apkar Apkarian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 94, "start_date": "2016-08", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2022-11-07", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02986334" }, { "nct_id": "NCT02174263", "title": "Tocilizumab for Chronic Graft-versus-Host Disease Treatment", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "tocilizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-05-06", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Rochester, Minnesota • Nashville, Tennessee + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02174263" }, { "nct_id": "NCT02961114", "title": "Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "BPH", "Nocturia", "BPH With Urinary Obstruction", "Prostatism", "Prostate Inflammation" ], "interventions": [ { "name": "Microcannula Harvest Adipose", "type": "PROCEDURE" }, { "name": "Centricyte 1000", "type": "DEVICE" }, { "name": "IV Sterile Normal Saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DEVICE", "BIOLOGICAL" ], "sponsor": "Robert W. Alexander, MD, FICS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "30 Years to 80 Years · Male only" }, "enrollment_count": 0, "start_date": "2019-11-01", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 2, "location_summary": "Stevensville, Montana", "locations": [ { "city": "Stevensville", "state": "Montana" }, { "city": "Stevensville", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02961114" }, { "nct_id": "NCT00660530", "title": "Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperphosphatemia", "Kidney Disease" ], "interventions": [ { "name": "Lanthanum Carbonate Chewable Product", "type": "DRUG" }, { "name": "Lanthanum carbonate crushed powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2008-01", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-05-22T05:49:33.464Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660530" } ] }